MIGRAINE THERAPEUTIC MARKET ANALYSIS

Regional Analysis

Global Migraine Therapeutic Market: Regional Insights

Based on geography, the global migraine therapeutics is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, North America is expected to gain highest share in the market over the forecast period due to the high prevalence of migraine and rise in awareness among people about migraine and its therapeutics in this region. For instance, according to the Migraine Research Foundation, migraines affect more than 39 million people in the United States and women are three times more likely to get migraines than men. According to the Migraine Institute, around 43% of U.S. women and 18% of men will experience migraines at some point in their life. Thus, there is an increasing demand for migraine therapeutics in the United States.

Asia Pacific is also expected to witness robust growth in the global migraine therapeutic market due to the rise in burden of migraine, increasing adoption of novel therapeutics, and the large target population in the region. For instance, according to a 2019 Study by Lancet Global Health, more than 213 million people in India were found to be suffering from migraine in 2019 while 60% of these cases were reported by women. The prevalence of migraine was higher in women aged 35-59 years than in men of the same age. This in turn has increased and/or increasing the demand for migraine therapeutics in India, driving the market growth.

Figure 1. Global Migraine Therapeutic Market Share (%), by Region, 2022

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC Countries, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa